2019年欧洲27国黑色素瘤诊疗学科调查
该研究于2019年2月1日至8月1日对27个欧洲国家黑色素瘤中心的专家进行网络调查,收集诊断技术、手术与药物治疗、诊疗组织及教育数据,并与国家卫生经济指标和死亡率-发病率比(MIR)做单变量线性回归分析。结果显示人均卫生支出高、全科医生和外科医生密度高的国家MIR更低,且全科医生和皮肤科医生更多参与黑色素瘤检测,皮肤科医生更常用皮肤镜并参与各期随访。
要点
- 人均卫生支出高及全科医生、外科医生密度高的国家黑色素瘤MIR更低。
- 在这些国家,全科医生和皮肤科医生参与黑色素瘤检测,皮肤科医生皮肤镜使用率高。
- 皮肤科医生参与所有分期随访,肿瘤内科医生和皮肤肿瘤医生共同实施系统治疗。
核心结论
- 加强全科医生参与黑色素瘤检测、提高皮肤科医生在皮肤镜、皮肤外科、随访和系统治疗中的参与度,并为病理科、外科、皮肤科和肿瘤内科提供持续皮肤肿瘤学培训,是优化黑色素瘤诊疗路径的必要条件。
研究设计与样本
- 2019年2月1日至8月1日对27个欧洲国家黑色素瘤中心专家进行网络调查,收集诊断技术、手术和药物治疗、诊疗组织及教育数据。
- 采用单变量线性回归分析数据与国家卫生经济指标及死亡率-发病率比(MIR)的相关性,使用SPSS软件,统计显著性设为P<0.05。
主要发现
- 人均卫生支出高、每百万居民全科医生和外科医生数量多的国家MIR更低。
- 在这些国家,全科医生和皮肤科医生参与黑色素瘤检测,高比例皮肤科医生使用皮肤镜并参与所有分期随访。
- 肿瘤内科医生和皮肤肿瘤医生共同实施系统治疗,患者在前哨淋巴结活检和多学科肿瘤委员会治疗方面可及性更好。
临床怎么用
- 应加强全科医生在黑色素瘤检测中的作用。
- 应提高高培训水平皮肤科医生在皮肤镜、皮肤外科、随访和系统治疗中的参与度。
- 应为病理科、外科、皮肤科和肿瘤内科提供持续的皮肤肿瘤学培训。
局限性
- 本研究为首次粗略估计,需基于临床黑色素瘤登记系统的全面分析来更准确评估这些初步见解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The incidence of melanoma is increasing. This places significant burden on societies to provide efficient cancer care. The European Cancer Organisation recently published the essential requirements for quality melanoma care. The present study is aimed for the first time to roughly estimate the extent to which these requirements have been met in Europe. MATERIALS AND METHODS: A web-based survey of experts from melanoma centres in 27 European countries was conducted from 1 February to 1 August 2019. Data on diagnostic techniques, surgical and medical treatment, organization of cancer care and education were collected and correlated with national health and economic indicators and mortality-to-incidence ratio (MIR) as a surrogate for survival. Univariate linear regression analysis was performed to evaluate the correlations. SPSS software was used. Statistical significance was set at P < 0.05. RESULTS: The MIR was lower in countries with a high health expenditure per capita and with a higher numbers of general practitioners (GPs) and surgeons (SURG) per million inhabitants. In these countries, GPs and dermatologists (DER) were involved in melanoma detection; high percentage of DER used dermatoscopy and were involved in the follow-up of all melanoma stages; both medical oncologists (ONC) and dermato-oncologists administered systemic treatments; and patients had better access to sentinel lymph node biopsy and were treated within multidisciplinary tumour boards. CONCLUSION: Based on these first estimates, the greater involvement of GPs in melanoma detection; the greater involvement of highly trained DER in dermatoscopy, dermatosurgery, follow-up and the systemic treatment of melanoma; and the provision of ongoing dermato-oncology training for pathologists, SURG, DER and ONC are necessary to provide an optimal melanoma care pathway. A comprehensive analysis of the melanoma care pathway based on clinical melanoma registries will be needed to more accurately evaluate these first insights.
引用
- Kandolf-Sekulovic L, Peris K, Stratigos A, et al. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. J Eur Acad Dermatol Venereol. 2021. PMID: 33326646. doi:10.1111/jdv.17086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。